Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.40
HCM's Cash-to-Debt is ranked higher than
51% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. HCM: 2.40 )
Ranked among companies with meaningful Cash-to-Debt only.
HCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: 1.79 Max: 5.06
Current: 2.4
0.64
5.06
Equity-to-Asset 0.55
HCM's Equity-to-Asset is ranked lower than
62% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. HCM: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
HCM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.44 Max: 0.55
Current: 0.55
0.19
0.55
Debt-to-Equity 0.25
HCM's Debt-to-Equity is ranked higher than
56% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. HCM: 0.25 )
Ranked among companies with meaningful Debt-to-Equity only.
HCM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13  Med: 0.46 Max: 1.36
Current: 0.25
0.13
1.36
Debt-to-EBITDA -1.07
HCM's Debt-to-EBITDA is ranked lower than
99.99% of the 511 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. HCM: -1.07 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HCM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -175.7  Med: -0.94 Max: 10.33
Current: -1.07
-175.7
10.33
Piotroski F-Score: 5
Altman Z-Score: 14.62
Beneish M-Score: -1.59
WACC vs ROIC
11.57%
-38.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -19.75
HCM's Operating Margin % is ranked lower than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.71 vs. HCM: -19.75 )
Ranked among companies with meaningful Operating Margin % only.
HCM' s Operating Margin % Range Over the Past 10 Years
Min: -21.61  Med: -4.82 Max: 58.29
Current: -19.75
-21.61
58.29
Net Margin % 5.45
HCM's Net Margin % is ranked lower than
52% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. HCM: 5.45 )
Ranked among companies with meaningful Net Margin % only.
HCM' s Net Margin % Range Over the Past 10 Years
Min: -26.4  Med: -2.34 Max: 16.27
Current: 5.45
-26.4
16.27
ROE % 7.30
HCM's ROE % is ranked higher than
52% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. HCM: 7.30 )
Ranked among companies with meaningful ROE % only.
HCM' s ROE % Range Over the Past 10 Years
Min: -57.96  Med: -11.5 Max: 9.22
Current: 7.3
-57.96
9.22
ROA % 3.99
HCM's ROA % is ranked higher than
53% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. HCM: 3.99 )
Ranked among companies with meaningful ROA % only.
HCM' s ROA % Range Over the Past 10 Years
Min: -16.75  Med: -1.69 Max: 4.38
Current: 3.99
-16.75
4.38
ROC (Joel Greenblatt) % -429.35
HCM's ROC (Joel Greenblatt) % is ranked lower than
88% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.46 vs. HCM: -429.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -471.68  Med: -17.31 Max: 193.62
Current: -429.35
-471.68
193.62
3-Year Revenue Growth Rate 75.90
HCM's 3-Year Revenue Growth Rate is ranked higher than
97% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. HCM: 75.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.8  Med: 24.5 Max: 100.1
Current: 75.9
-41.8
100.1
3-Year EPS without NRI Growth Rate 23.60
HCM's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. HCM: 23.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -10  Med: 17.85 Max: 30.1
Current: 23.6
-10
30.1
GuruFocus has detected 1 Warning Sign with Hutchison China Meditech Ltd HCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HCM's 30-Y Financials

Financials (Next Earnings Date: 2018-03-13)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

HCM Guru Trades in Q1 2017

Jim Simons 31,000 sh (New)
Matthews Asia Small Companies Fund 223,300 sh (New)
» More
Q2 2017

HCM Guru Trades in Q2 2017

Jim Simons 76,000 sh (+145.16%)
Matthews Asia Small Companies Fund 210,900 sh (-5.55%)
» More
Q3 2017

HCM Guru Trades in Q3 2017

Jim Simons 91,200 sh (+20.00%)
Matthews Asia Small Companies Fund 210,900 sh (unchged)
» More
Q4 2017

HCM Guru Trades in Q4 2017

Pioneer Investments 51,999 sh (New)
Matthews Asia Small Companies Fund 208,000 sh (-1.38%)
Jim Simons 69,800 sh (-23.46%)
» More
» Details

Insider Trades

Latest Guru Trades with HCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:SHSE:600466, TSE:9987, SZSE:002019, NSE:TORNTPHARM, SZSE:300146, OTCPK:GWPRF, SZSE:002424, SHSE:600666, BOM:500660, HKSE:02186, XKRX:068760, SZSE:002399, TSE:2784, SHSE:600572, LSE:DPH, BOM:524816, SZSE:002422, SZSE:000566, SHSE:900907, SZSE:000591 » details
Traded in other countries:H7T.Germany, HCM.UK, HNCMF.USA,
Headquarter Location:Hong Kong
Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform aimed at discovering and developing therapeutics in oncology and autoimmune diseases.

Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform. Hutchison's innovation platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases. The company's commercial platform includes the manufacturing, marketing, and distribution of prescription and over-the-counter pharmaceuticals in China as well as certain consumer products in Hong Kong. The vast majority of the company's revenue is generated through its commercial platform.

Top Ranked Articles about Hutchison China Meditech Ltd

The Evolution of My Research Process - Part II The time travel research method
In my previous post I reflected upon the first three phases of research I went through as an evolving value investor. Today’s post will be focused on a key stage of my evolution. Read more...

Ratios

vs
industry
vs
history
PE Ratio 256.11
HCM's PE Ratio is ranked lower than
96% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.21 vs. HCM: 256.11 )
Ranked among companies with meaningful PE Ratio only.
HCM' s PE Ratio Range Over the Past 10 Years
Min: 89.28  Med: 169.05 Max: 500.66
Current: 256.11
89.28
500.66
PE Ratio without NRI 256.11
HCM's PE Ratio without NRI is ranked lower than
96% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.28 vs. HCM: 256.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
HCM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 37.25  Med: 138.45 Max: 364.53
Current: 256.11
37.25
364.53
Price-to-Owner-Earnings 229.35
HCM's Price-to-Owner-Earnings is ranked lower than
94% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.28 vs. HCM: 229.35 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HCM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.48  Med: 257.71 Max: 3857.14
Current: 229.35
26.48
3857.14
PB Ratio 18.93
HCM's PB Ratio is ranked lower than
93% of the 825 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. HCM: 18.93 )
Ranked among companies with meaningful PB Ratio only.
HCM' s PB Ratio Range Over the Past 10 Years
Min: 0.36  Med: 6.07 Max: 57.32
Current: 18.93
0.36
57.32
PS Ratio 15.97
HCM's PS Ratio is ranked lower than
84% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. HCM: 15.97 )
Ranked among companies with meaningful PS Ratio only.
HCM' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 7.65 Max: 28.49
Current: 15.97
0.31
28.49
EV-to-EBIT -83.50
HCM's EV-to-EBIT is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.21 vs. HCM: -83.50 )
Ranked among companies with meaningful EV-to-EBIT only.
HCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -262.5  Med: -30.6 Max: 119.9
Current: -83.5
-262.5
119.9
EV-to-EBITDA -88.35
HCM's EV-to-EBITDA is ranked lower than
99.99% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. HCM: -88.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
HCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8742.2  Med: -11.4 Max: 176.4
Current: -88.35
-8742.2
176.4
EV-to-Revenue 16.09
HCM's EV-to-Revenue is ranked lower than
83% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. HCM: 16.09 )
Ranked among companies with meaningful EV-to-Revenue only.
HCM' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 7.5 Max: 28.9
Current: 16.09
0.1
28.9
Current Ratio 1.84
HCM's Current Ratio is ranked lower than
61% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. HCM: 1.84 )
Ranked among companies with meaningful Current Ratio only.
HCM' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.48 Max: 2.18
Current: 1.84
0.85
2.18
Quick Ratio 1.73
HCM's Quick Ratio is ranked lower than
53% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. HCM: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
HCM' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.25 Max: 2.08
Current: 1.73
0.84
2.08
Days Inventory 21.24
HCM's Days Inventory is ranked higher than
94% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.37 vs. HCM: 21.24 )
Ranked among companies with meaningful Days Inventory only.
HCM' s Days Inventory Range Over the Past 10 Years
Min: 17.86  Med: 127.27 Max: 448.99
Current: 21.24
17.86
448.99
Days Sales Outstanding 65.90
HCM's Days Sales Outstanding is ranked higher than
60% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.67 vs. HCM: 65.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
HCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.75  Med: 68.62 Max: 155.16
Current: 65.9
26.75
155.16
Days Payable 56.08
HCM's Days Payable is ranked lower than
64% of the 630 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.56 vs. HCM: 56.08 )
Ranked among companies with meaningful Days Payable only.
HCM' s Days Payable Range Over the Past 10 Years
Min: 53.45  Med: 69.98 Max: 91.09
Current: 56.08
53.45
91.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
HCM's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.00 vs. HCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.8  Med: -0.5 Max: 0
Current: -5.3
-11.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 160.57
HCM's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 512 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. HCM: 160.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.69  Med: 46.42 Max: 189.17
Current: 160.57
7.69
189.17
Price-to-Tangible-Book 18.94
HCM's Price-to-Tangible-Book is ranked lower than
91% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. HCM: 18.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.12  Med: 8.88 Max: 33.29
Current: 18.94
3.12
33.29
Price-to-Intrinsic-Value-Projected-FCF 46.19
HCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. HCM: 46.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 22.7 Max: 46.19
Current: 46.19
0
46.19
Price-to-Median-PS-Value 2.09
HCM's Price-to-Median-PS-Value is ranked lower than
99.99% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. HCM: 2.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.75 Max: 2.09
Current: 2.09
0
2.09
Price-to-Graham-Number 14.85
HCM's Price-to-Graham-Number is ranked lower than
97% of the 456 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.96 vs. HCM: 14.85 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HCM' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.81  Med: 5.25 Max: 14.86
Current: 14.85
2.81
14.86
Earnings Yield (Greenblatt) % -1.20
HCM's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 868 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.18 vs. HCM: -1.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -233.8  Med: -1 Max: 3.4
Current: -1.2
-233.8
3.4

More Statistics

Revenue (TTM) (Mil) $238.15
EPS (TTM) $ 0.11
Short Percentage of Float0.00%
52-Week Range $12.62 - 42.25
Shares Outstanding (Mil)132.89 (ADR)

Analyst Estimate

Dec17 Dec19 Dec20
Revenue (Mil $) 239 344 456
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.04 0.53 0.54
EPS without NRI ($) 0.04 0.53 0.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}